{"schema_version":"1","generated_at":"2026-11-18T01:08:41.813Z","data_as_of":"2026-11-12","url":"https://www.findmykol.com/kol/manisha-shah","json_url":"https://www.findmykol.com/kol/manisha-shah/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"manisha-shah","name":"Manisha Shah","credential":"MD","title":"Associate Professor of Internal Medicine","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Gastrointestinal","therapeutic_areas":["Gastrointestinal","Oncology"],"institution":"The Ohio State University Medical Center","institution_url":"https://www.findmykol.com/institution/the-ohio-state-university","city":"Columbus","state":"OH","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1679581896"},"summary":"Manisha Shah is Associate Professor of Internal Medicine at The Ohio State University Medical Center. ClinicalTrials.gov lists 10 registered studies with this person as an investigator.","overview":{"text":"Manisha Shah, M.D., is Associate Professor of Internal Medicine at The Ohio State University Medical Center. It also documents an investigator role on 10 registered clinical trials, 3 NIH-funded awards (2002–2020).","bullets":["Top research focus: Carcinoid Tumor","10 registered trials on ClinicalTrials.gov"],"generated_at":"2026-11-17"},"focus":{"indications":[{"label":"Carcinoid Tumor","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Gastroesophageal Cancer","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Stomach Neoplasms","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Thyroid cancer, follicular","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Thyroid Cancer, Papillary","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Adenoma, Islet Cell","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Carcinoma, Islet Cell","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Carcinoma, Medullary","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Carcinoma, Papillary","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Gastrinoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Glucagonoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Head & Neck Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Insulinoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Somatostatinoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Carcinoid Tumor","Gastroesophageal Cancer","Stomach Neoplasms","Thyroid Cancer, Papillary","Thyroid cancer, follicular","Adenoma, Islet Cell","Carcinoma, Islet Cell","Carcinoma, Medullary","Carcinoma, Papillary","Gastrinoma","Glucagonoma","Head & Neck Cancer","Insulinoma","Somatostatinoma"],"works_with":{"total":3,"shown":3,"withheld":0,"rows":[{"name":"National Cancer Institute (NCI)","trials":7,"payments":0,"mentions":7},{"name":"Ohio State University Comprehensive Cancer Center","trials":2,"payments":0,"mentions":2},{"name":"Manisha Shah","trials":1,"payments":0,"mentions":1}]}},"scholarship":{"note":"Research metrics are not shown for this record: either no confident publication match for this name, or more than one clinician shares the matched author record."},"trials":{"count":10,"shown":3,"withheld":7,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT01811212","title":"Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer","phase":"PHASE2","status":"COMPLETED","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT01811212","trial_url":"https://www.findmykol.com/trial/NCT01811212"},{"nct":"NCT01713972","title":"Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors","phase":"PHASE1","status":"COMPLETED","role":"Investigator","sponsor":"Manisha Shah","source_url":"https://clinicaltrials.gov/study/NCT01713972","trial_url":"https://www.findmykol.com/trial/NCT01713972"},{"nct":"NCT00134043","title":"Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer","phase":"PHASE2","status":"COMPLETED","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT00134043","trial_url":"https://www.findmykol.com/trial/NCT00134043"}],"source":"trials"},"payments":{"company_count":0,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1679581896","source":"payments"},"prescribing":{"data_year":2021,"areas_total":2,"areas_shown":2,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":69.2,"classes_total":2,"classes":[{"class":"Antidiarrheal","setting":"prescribed","share_pct":38.5,"drugs":[{"name":"Diphenoxylate-Atropine","share_pct":100}],"max_beneficiaries":null},{"class":"Corticosteroid","setting":"prescribed","share_pct":30.8,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":30.8,"classes_total":1,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":30.8,"drugs":[{"name":"Lenvima","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2021,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":3,"fiscal_years":{"first":2002,"last":2020},"rows_total":7,"shown":3,"withheld":4,"rows":[{"project":"R01CA246553","title":"Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer","fiscal_year":2020,"amount_usd":226665,"organization":"BECKMAN RESEARCH INSTITUTE/CITY OF HOPE","source_url":"https://reporter.nih.gov/quickSearch/R01CA246553"},{"project":"R01CA246553","title":"Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer","fiscal_year":2020,"amount_usd":193780,"organization":"OHIO STATE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R01CA246553"},{"project":"P41RR002584","title":"CONGESTIVE HEART FAILURE AND SKELETAL METABOLISM","fiscal_year":2009,"amount_usd":17838,"organization":"UT SOUTHWESTERN MEDICAL CENTER","source_url":"https://reporter.nih.gov/quickSearch/P41RR002584"}],"source":"grants"},"publications":{"total":0,"shown":0,"withheld":0,"recent":[],"source":"works"},"presence":{"mentions":{"total":2,"shown":2,"rows":[{"url":"https://convenehealthcare.com/specialists/profile/dr-manisha-shah-columbus","platform":"other","status":"provisional"},{"url":"https://www.medifind.com/doctors/manisha-shah/7526675","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"MD","source_url":"https://www.healthgrades.com/physician/dr-manisha-shah-ybyqk","status":"provisional","collected_at":"2026-11-12"}]},"media":{"total":3,"shown":3,"rows":[{"value":"New York Times 2002 feature on carcinoid tumor naming Manisha Shah as assistant director of the neuroendocrine tumor clinic at James Cancer Hospital, Columbus","source_url":"https://www.nytimes.com/2002/03/26/health/cases-rare-tumor-is-deceptive-and-deadly.html","status":"provisional","collected_at":"2026-11-12"},{"value":"CBS Detroit feature on Aretha Franklin's cancer doctors, naming Manisha Shah of Ohio State University","source_url":"https://www.cbsnews.com/detroit/news/aretha-franklins-cancer-doctors-recall-her-grace-grit/","status":"provisional","collected_at":"2026-11-12"},{"value":"SWOG news on immunotherapy combination for neuroendocrine tumors quoting Manisha Shah, MD, of The Ohio State University","source_url":"https://www.swog.org/news-events/news/2020/02/25/immuno-rx-shrinks-rare-neuroendocrine-tumors","status":"provisional","collected_at":"2026-11-12"}]}},"similar":[{"name":"Eric Van Cutsem","slug":"eric-cutsem","institution":"University Hospitals Leuven (UZ Leuven)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/eric-cutsem","json_url":"https://www.findmykol.com/kol/eric-cutsem/profile.json"},{"name":"Josep Tabernero","slug":"josep-tabernero","institution":"Vall d'Hebron Institute of Oncology (VHIO)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/josep-tabernero","json_url":"https://www.findmykol.com/kol/josep-tabernero/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Charles Fuchs","slug":"charles-fuchs","institution":"Tubulis GmbH","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/charles-fuchs","json_url":"https://www.findmykol.com/kol/charles-fuchs/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":7,"funding":4}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-12"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2021},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-11-12"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"}},"methodology_url":"https://www.findmykol.com/about#methodology"}